Overview

Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status:
Active, not recruiting

Trial end date:
2033-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Kite Pharma, Inc.
Kite, A Gilead Company

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab
Cyclophosphamide
Fludarabine